Database Query Results : Lutein, ,

Lut, Lutein: Click to Expand ⟱
Features:

Lutein (L; xanthophyll carotenoid) — dietary pigment concentrated in the macula (with zeaxanthin) forming macular pigment; sourced from leafy greens (kale/spinach), corn, egg yolk, and supplements (often paired with zeaxanthin).

Primary mechanisms (conceptual rank):
1) Blue-light filtering + macular pigment optical protection
2) Antioxidant / anti–lipid-peroxidation (↓ ROS burden in retina and other tissues)
3) Anti-inflammatory signaling modulation (e.g., NF-κB tone; context-dependent)
4) Secondary signaling effects in cancer models (PI3K/AKT, MAPK, apoptosis; high concentration only)

Bioavailability / PK relevance: Fat-soluble; absorption improves with dietary fat; plasma lutein rises dose-dependently with supplementation and accumulates in retina (macular pigment). Long-term dosing (weeks–months) is typical for tissue effects.

In-vitro vs oral exposure: Most direct anti-cancer cytotoxicity requires supra-physiologic concentrations (high concentration only); clinical relevance is strongest for eye outcomes (AMD risk progression).

Clinical evidence status: Supported within AREDS2-style formulations for reducing progression risk in intermediate → advanced AMD (eye-specific benefit); cancer evidence remains preclinical.

Lutein
-Kale, spinach, parsley, corn, egg yolks, peas
-Breast cancer: Inverse correlation with dietary intake
- Potent antioxidant, scavenges ROS (reactive oxygen species)
-Downregulates NF-κB and other inflammatory pathways
-Promotes apoptosis in cancer cells
-inhibits angiogenesis

Lutein — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↔ / ↓ (context-dependent; high concentration only for cytotoxicity) ↓ (primary) P/R Antioxidant buffering Core physiologic role is antioxidant protection (notably retina); tumor redox effects vary and are often concentration/model dependent.
2 NRF2 antioxidant-response program ↔ / ↑ (context-dependent) ↑ R/G Stress-defense upshift Typically consistent with cytoprotection; in tumors, NRF2 upshift can be double-edged (potential resistance context).
3 NF-κB / inflammatory cytokine programs ↓ (model-dependent) ↓ R/G Anti-inflammatory signaling Relevant to systemic low-grade inflammation framing in AMD; cancer relevance varies by tumor microenvironment context.
4 HIF-1α / angiogenesis coupling ↓ (model-dependent; high concentration only) ↔ G Reduced hypoxia-adaptation signaling (preclinical) Reported in some preclinical models; not a dominant clinically validated axis for lutein.
5 PI3K/AKT and MAPK (ERK/JNK) ↓ or ↔ (model-dependent; high concentration only) ↔ R/G Secondary survival-signaling modulation Observed in vitro with extract/compound exposure; not established at typical supplement systemic exposure.
6 Apoptosis (caspases; mitochondrial) ↑ (high concentration only) ↔ R/G Experimental cytotoxicity Anti-cancer apoptosis effects usually require supra-physiologic exposure vs oral supplementation.
7 Ferroptosis susceptibility (PUFA/lipid ROS context) ↔ (limited; context-dependent) ↔ R/G Not a canonical lutein axis Lutein is more classically antioxidant; ferroptosis linkage is not central or consistently demonstrated.
8 Ca²⁺ signaling ↔ ↔ P/R No primary role Not a recognized dominant mechanism for lutein.
9 Clinical Translation Constraint ↓ (constraint) ↓ (constraint) — Oncology concentration gap Strongest human data are eye-related (AREDS2); most direct oncology mechanisms rely on higher in-vitro exposure than typical systemic levels.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr


Lutein — AD relevance: Lutein preferentially accumulates in the brain and has been linked to neural efficiency and modest cognitive performance effects in older adults; mechanisms emphasize antioxidant/anti-inflammatory protection and membrane/synaptic support. Evidence is supportive but not disease-modifying.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↓ ROS; membrane protection)
2) ↓ Neuroinflammation (cytokine/NF-κB tone; context-dependent)
3) ↑ Neural efficiency / connectivity signals (human MRI/fMRI supplementation studies)
4) Secondary Aβ/tau pathway effects (preclinical emphasis)

Bioavailability / PK relevance: Chronic intake increases circulating lutein and is associated with higher macular pigment (used as a biomarker linked to brain lutein status). Effects are generally time-dependent (months).

Clinical evidence status: Small RCTs and imaging trials in older adults show signals for neural efficiency/cognition; AD-specific clinical evidence remains limited.

Lutein — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / lipid peroxidation ↓ P/R Reduced oxidative burden Central neuroprotective rationale; aligns with membrane and mitochondrial resilience concepts.
2 Neuroinflammation (NF-κB, cytokine tone) ↓ (context-dependent) R/G Lower inflammatory stress Often framed as systemic/low-grade inflammation modulation; human mechanistic specificity varies.
3 Neural efficiency / network connectivity (functional imaging outcomes) ↑ G More efficient task-related activation Randomized trials report changes in brain function metrics and some cognitive measures with L (± Z) supplementation.
4 Synaptic membrane support (lipid microdomain stability) ↑ (supportive) G Signal transduction support Mechanistic framing consistent with carotenoid localization in neural tissue; largely supportive/inferential.
5 NRF2 axis ↔ / ↑ (adaptive; context-dependent) R/G Stress-defense regulation Potential secondary antioxidant-response involvement; not always directly measured in human trials.
6 Aβ / tau-associated pathology ↔ / ↓ (preclinical) G Reduced pathological burden (hypothesis) Evidence is stronger in models than in AD biomarker-confirmed human studies.
7 Ca²⁺ homeostasis / excitotoxic vulnerability ↔ P/R No primary role Not a canonical lutein mechanism; include only if model explicitly measures Ca²⁺/excitotoxic endpoints.
8 Clinical Translation Constraint ↓ (constraint) — Supportive, not disease-modifying Signals in small RCTs/imaging studies; effect sizes modest and depend on duration, baseline status, and co-nutrients (e.g., zeaxanthin).

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Scientific Papers found: Click to Expand⟱
3988- betaCar,  Lut,  Zeax,    Effects of egg consumption on carotenoid absorption from co-consumed, raw vegetables
- Trial, AD, NA
*eff↑, *eff↑, *eff↑,
3984- Lut,  VitE,    Serum concentrations of vitamin E and carotenoids are altered in Alzheimer's disease: A case-control study
- Study, AD, NA
*other↓,
4232- Lut,    Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder
- in-vivo, NA, NA
*BDNF↑, *Mood↑, *neuroG↑, *TrkB↑,
4231- Lut,    Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application
- Review, AD, NA
*PSD95↑, *BDNF↑, *SOD↑, *GSTA1↑, *MDA↑, *Casp3↓, *Mood↑, *antiOx↑, *Apoptosis↓, *Inflam↓, *ER Stress↓,
4195- Lut,  Zeax,    Low Xanthophylls, Retinol, Lycopene, and Tocopherols in Grey and White Matter of Brains with Alzheimer’s Disease
- Human, AD, NA
*Risk↓, *cognitive↑, *other↓,
4194- Lut,  Zeax,    Effect of macular pigment carotenoids on cognitive functions: A systematic review
- Review, NA, NA
*MPOD↑, *cognitive↑, *memory↑,
4193- Lut,  Zeax,    Effects of a Lutein and Zeaxanthin Intervention on Cognitive Function: A Randomized, Double-Masked, Placebo-Controlled Trial of Younger Healthy Adults
- Trial, NA, NA
*MPOD↑, *cognitive↑, *memory↑,
4192- Lut,  Zeax,    Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study
- Trial, NA, NA
*MPOD↑, *cognitive↑, *memory↑, *BDNF↑,
3983- Lut,  Zeax,    The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial
- Trial, AD, NA
*other↑, *other↑, *cognitive∅,
3982- Lut,  Zeax,    Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined
- Trial, AD, NA
*memory↑, *eff↑, *Mood↑,
3981- Lut,  Zeax,  VitE,    Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
- Trial, AD, NA
*memory↑, *other↑, *cognitive↑,
3980- Lut,  Zeax,    Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease
- Trial, AD, NA
*eff↑, *memory↑, *Mood↑, *QoL↑,
3979- Lut,    Increases in Plasma Lutein through Supplementation Are Correlated with Increases in Physical Activity and Reductions in Sedentary Time in Older Adults
- Trial, AD, NA
*other↑, *QoL↑,
3978- Lut,  Zeax,    Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial
- Trial, AD, NA
*cognitive↑, *Inflam↓,
3977- Lut,  Zeax,    Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults
- Trial, AD, NA
*Aβ↓, *cognitive↑, *Mood↑,
3816- Lyco,  Lut,  Zeax,    Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults
- Review, AD, NA
*Risk↓,
4191- Zeax,  Lut,    Effects of macular xanthophyll supplementation on brain-derived neurotrophic factor, pro-inflammatory cytokines, and cognitive performance
- Trial, AD, NA
*BDNF↑, *IL1β↓, *cognitive↑, *memory↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 17

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   GSTA1↑, 1,   MDA↑, 1,   MPOD↑, 3,   SOD↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Casp3↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 2,   other↑, 4,  

Protein Folding & ER Stress ⓘ

ER Stress↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

neuroG↑, 1,  

Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,   Inflam↓, 2,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 4,   PSD95↑, 1,   TrkB↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 5,  

Functional Outcomes ⓘ

cognitive↑, 8,   cognitive∅, 1,   memory↑, 7,   Mood↑, 5,   QoL↑, 2,   Risk↓, 2,  
Total Targets: 24

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:349  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page